PCVX logo

Vaxcyte (PCVX) Stock

Profile

Full Name:

Vaxcyte, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 June 2020

Indexes:

Not included

Description:

Vaxcyte, known as PCVX, is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases. They use advanced technology to create effective and safe vaccines, aiming to improve public health and address unmet medical needs globally.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 05, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

24 Dec '24 BTIG
Buy
20 Dec '24 Goldman Sachs
Buy
06 Nov '24 Needham
Buy
06 Nov '24 Cantor Fitzgerald
Overweight
10 Sept '24 Mizuho
Outperform
04 Sept '24 B of A Securities
Buy
03 Sept '24 Needham
Buy
03 Sept '24 Leerink Partners
Outperform
03 Sept '24 Jefferies
Buy
03 Sept '24 BTIG
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
PCVX
globenewswire.com30 January 2025

SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on developing advanced vaccines to combat bacterial diseases, has announced that its management will take part in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York. This event is scheduled for Thursday, February 6, 2025, at 9:30 a.m. ET / 6:30 a.m. PT.

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
PCVX
globenewswire.com30 January 2025

On January 30, 2025, Kuehn Law, PLLC, a law firm focused on shareholder litigation, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) violated their responsibilities to shareholders. The investigation is focused on possible self-dealing actions. Shareholders might be eligible for compensation and changes in corporate governance.

Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?
PCVX
Insider Monkey18 January 2025

We have put together a list of the 10 Best Russell 2000 Stocks to Invest in Based on Analyst Recommendations. In this article, we will examine how Vaxcyte, Inc. (NASDAQ:PCVX) compares to other top Russell 2000 stocks recommended by analysts. The Russell 2000 Index is a popular benchmark that...

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
PCVX
seekingalpha.com15 January 2025

Since August 2023, Vaxcyte's stock has increased by 68% due to advancements in its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, which targets 95.6% of serotypes, has been chosen for Phase 3 trials, with results anticipated in 2026. The company also has a strong financial standing, with more than $3 billion in cash and investments, allowing for strategic flexibility and longer timelines.

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
PCVX
prnewswire.com07 January 2025

On January 7, 2025, Kuehn Law, PLLC, a law firm focused on shareholder litigation, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) violated their responsibilities to shareholders. The investigation is focused on possible self-dealing actions.

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
PCVX
globenewswire.com19 December 2024

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a law firm focused on shareholder lawsuits, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) failed to fulfill their responsibilities to shareholders. The inquiry is related to possible self-dealing actions. Shareholders might be eligible for compensation and changes in corporate governance.

Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
PCVX
Insider Monkey29 November 2024

Carillon Tower Advisers, an investment management firm, published its third quarter 2024 investor letter for the "Carillon Eagle Small Cap Growth Fund." You can download the letter here. After facing losses in the second quarter, small-cap stocks saw a significant rise in the third quarter, with the Russell 2000 Growth Index increasing by 8.41%, although it still lagged behind the Russell 2000 Value Index.

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
PCVX
globenewswire.com12 November 2024

The FDA has approved the Investigational New Drug Application for VAX-31 for infants, and the company aims to start the Phase 2 study by the end of January 2025. For adults, the FDA has given Breakthrough Therapy Designation to VAX-31, and the company intends to begin the Phase 3 pivotal study by mid-2025.

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
PCVX
globenewswire.com11 September 2024

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on developing advanced vaccines to combat bacterial diseases, has announced that its management will take part in a fireside chat at the 2024 Cantor Global Healthcare Conference. This event is scheduled for Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
PCVX
seekingalpha.com08 September 2024

Vaxcyte's XpressCF platform allows for the creation of vaccines that can target a wide range of diseases, addressing the challenges of older cell-based methods. The company's main products, VAX-31 and VAX-24, focus on invasive pneumococcal disease (IPD) and offer better protection than other options available. The early results for VAX-31 showed it is safe and effective, setting it up for further testing in Phase 3 trials by mid-2025.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Vaxcyte?
  • What is the ticker symbol for Vaxcyte?
  • Does Vaxcyte pay dividends?
  • What sector is Vaxcyte in?
  • What industry is Vaxcyte in?
  • What country is Vaxcyte based in?
  • When did Vaxcyte go public?
  • Is Vaxcyte in the S&P 500?
  • Is Vaxcyte in the NASDAQ 100?
  • Is Vaxcyte in the Dow Jones?
  • When was Vaxcyte's last earnings report?
  • When does Vaxcyte report earnings?
  • Should I buy Vaxcyte stock now?

What is the primary business of Vaxcyte?

Vaxcyte, known as PCVX, is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases. They use advanced technology to create effective and safe vaccines, aiming to improve public health and address unmet medical needs globally.

What is the ticker symbol for Vaxcyte?

The ticker symbol for Vaxcyte is NASDAQ:PCVX

Does Vaxcyte pay dividends?

No, Vaxcyte does not pay dividends

What sector is Vaxcyte in?

Vaxcyte is in the Healthcare sector

What industry is Vaxcyte in?

Vaxcyte is in the Biotechnology industry

What country is Vaxcyte based in?

Vaxcyte is headquartered in United States

When did Vaxcyte go public?

Vaxcyte's initial public offering (IPO) was on 12 June 2020

Is Vaxcyte in the S&P 500?

No, Vaxcyte is not included in the S&P 500 index

Is Vaxcyte in the NASDAQ 100?

No, Vaxcyte is not included in the NASDAQ 100 index

Is Vaxcyte in the Dow Jones?

No, Vaxcyte is not included in the Dow Jones index

When was Vaxcyte's last earnings report?

Vaxcyte's most recent earnings report was on 5 November 2024

When does Vaxcyte report earnings?

The next expected earnings date for Vaxcyte is 27 February 2025

Should I buy Vaxcyte stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions